Volume 20, Number 11—November 2014
Research
Drug-Resistant Candida glabrata Infection in Cancer Patients
Table 1
Basic demographic, clinical, and laboratory characteristics for 144 cancer patients with 146 episodes of Candida glabrata fungemia, MD Anderson Cancer Center, Houston, Texas, USA, March 2005–September 2013*
Characteristic | No. (%) |
---|---|
Host | |
Age, y, mean (± SD), range | 55.5 (± 14.52), 12–85 |
Male sex | 74 (51.38) |
Solid tumor† | 98 (68.05) |
Hematologic malignancy | 46 (31.95) |
Leukemia | 22 (15.3) |
Acute myeloid leukemia | 17 (11.81) |
Acute lymphoblastic leukemia | 5 (3.47) |
Lymphoma | 14 (9.72) |
Multiple myeloma | 4 (2.77) |
Myelodysplastic syndrome | 2 (1.38) |
Myelohyperplastic syndrome | 4 (2.77) |
Hematopoietic stem cell transplantation |
16 (11.11) |
Clinical disease | |
Intensive care unit stay | 59 (40.41) |
Mechanical ventilation | 27 (18.49) |
Presence of a central line | 131 (89.72) |
Total parenteral nutrition |
36 (24.65) |
Recent (within 1 mo before the day of candidemia) drug exposures | |
Chemotherapy | 69 (47.26) |
Any corticosteroids | 85 (58.21) |
Antibacterial drugs | 144 (98.63) |
Azoles | 44 (30.13) |
Echinocandins |
32 (21.91) |
Laboratory findings | |
Neutropenia, cells/μL | |
<500 | 28 (19.17) |
100–500 | 9 (6.16) |
<100 | 19 (13.14) |
Lymphopenia, cells/μL | |
<500 | 86 (58.9) |
<100 | 30 (20.54) |
Monocytopenia, <100 cells/μL | 39 (26.71) |
*All parameters were present on the day of candidemia, defined as the day of blood culture collection. Data are presented as absolute numbers (%) unless otherwise indicated for normally distributed variables or median numbers (25th–75th percentile) for variables that were not normally distributed.
†Tumor types were as follows: 47 (32.63%) gastrointestinal, 12 (8.33%) gynecologic, 9 (6.25%) genitourinary, 6 (4.16%) breast, 6 (4.16%) lung, 3 (2.08%) thyroid, 4 (2.77%) sarcomas, 3 (2.08%) head and neck, 2 (1.38%) central nervous system, and 6 (4.16%) other.
1Current affiliation: Harvard Medical School Brigham and Women’s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA